Publication:
Kidney transplantation: is it a solution to endothelial dysfunction?

dc.contributor.coauthorUreche, Carina
dc.contributor.coauthorCovic, Alexandra M.
dc.contributor.coauthorSekmen, Mert
dc.contributor.coauthorCovic, Adrian
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorTanrıöver, Cem
dc.contributor.kuauthorÇöpür, Sidar
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-01-19T10:31:58Z
dc.date.issued2023
dc.description.abstractBackground: Endothelial dysfunction is associated with elevated cardiovascular risk in patients with end-stage renal disease (ESRD). Kidney transplantation has demonstrated significant ability in reducing mortality and improving quality of life in recipients. Recent studies have also reported improvements in endothelial function following kidney transplantation; however, current literature is limited. Methods: We performed a systematic review of PubMed/Medline, Web of Science, Scopus, Cochrane Library, and CINAHL databases for prospective cohort studies that assessed endothelial function prior to and following kidney transplantation via various clinical markers. Follow-up duration ranged from 1 month to 1 year. A meta-analysis of pooled data was conducted using random-effect models for four key markers: brachial artery flow-mediated dilatation (FMD), high-sensitivity C-reactive protein (hsCRP), nitroglycerin-mediated dilation (NMD), and adiponectin. Results: We included nine studies in our final analysis with a total of 524 patients. Significant improvement of all four biomarkers was observed after transplantation. The mean difference was 2.81% (95% CI 1.92–3.71, p < 0.00001) for FMD, 17.27 mg/L (95% CI 5.82–28.72, p = 0.003) for hsCRP, 1.05%, (95% CI 0.56–1.54, p < 0.0001) for NMD, and 9.27 µg/mL (95% CI 5.96–12.57, p < 0.00001) for adiponectin. Conclusion: There is an immediate reversal of endothelial dysfunction in ESRD patients who undergo kidney transplantation, which may explain observed improvements in cardiovascular morbidity in transplant recipients. Future longitudinal studies are needed to understand possible re-emergence of endothelial dysfunction in the long-term postoperative period. © 2022, The Author(s), under exclusive licence to Springer Nature B.V.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue5
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume55
dc.identifier.doi10.1007/s11255-022-03415-x
dc.identifier.eissn1573-2584
dc.identifier.issn3011623
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85142128388
dc.identifier.urihttps://doi.org/10.1007/s11255-022-03415-x
dc.identifier.urihttps://hdl.handle.net/20.500.14288/26336
dc.identifier.wos886322600001
dc.keywordsAdiponectin
dc.keywordsEndothelial function
dc.keywordsInflammation
dc.keywordsKidney transplantation
dc.keywordsMortality
dc.language.isoeng
dc.publisherSpringer Science and Business Media B.V.
dc.relation.ispartofInternational Urology and Nephrology
dc.subjectMedicine
dc.titleKidney transplantation: is it a solution to endothelial dysfunction?
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorKanbay, Mehmet
local.contributor.kuauthorÇöpür, Sidar
local.contributor.kuauthorTanrıöver, Cem
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files